or Try an Advanced Search...

    Technical Analysis for PASG - Passage Bio, Inc.

    Grade Last Price % Change Price Change
    F 0.63 2.34% 0.01
    PASG closed up 2.34 percent on Friday, November 1, 2024, on 25 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    Earnings due: Nov 11
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical PASG trend table...
    Date Alert Name Type % Chg
    Bollinger Band Squeeze Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    20 DMA Support Bullish 2.34%
    Bollinger Band Squeeze Range Contraction 2.34%
    NR7 Range Contraction 2.34%
    NR7-2 Range Contraction 2.34%
    Down 3 Days in a Row Weakness 2.34%
    Bollinger Band Squeeze Range Contraction 0.93%
    NR7 Range Contraction 0.93%
    Older End-of-Day Signals for PASG ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 18 hours ago
    Up 5% about 18 hours ago
    Up 3% about 18 hours ago
    Possible NR7 about 18 hours ago
    10 DMA Support about 23 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    PASG Chart by TradingView
    Basic chart:

    Profile

    Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Organ Systems Rare Diseases Central Nervous System Disorders Nervous System Disorders Lipid Storage Disorders Monogenic Medicine Products Gm1 Rare Tadataka Yamada

    Is PASG a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 24 Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc
    Sep 23 Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
    Sep 19 Orbimed Advisors LLC Reduces Stake in Passage Bio Inc
    Sep 16 Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
    Aug 6 Passage Bio to Participate in Upcoming Investor Conferences
    Aug 1 Passage Bio gains after licensing deal with GEMMA Bio
    Aug 1 Jim Wilson, prominent gene therapy researcher, to depart UPenn
    Aug 1 Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
    Jul 21 Is Passage Bio (NASDAQ:PASG) In A Good Position To Invest In Growth?
    Jul 16 Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
    See more PASG news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.79
    52 Week Low 0.54
    Average Volume 243,062
    200-Day Moving Average 1.02
    50-Day Moving Average 0.66
    20-Day Moving Average 0.60
    10-Day Moving Average 0.62
    Average True Range 0.07
    RSI (14) 49.75
    ADX 18.18
    +DI 12.18
    -DI 12.88
    Chandelier Exit (Long, 3 ATRs) 0.50
    Chandelier Exit (Short, 3 ATRs) 0.74
    Upper Bollinger Bands 0.65
    Lower Bollinger Band 0.56
    Percent B (%b) 0.76
    BandWidth 15.80
    MACD Line -0.01
    MACD Signal Line -0.02
    MACD Histogram 0.0083
    Fundamentals Value
    Market Cap 34.5 Million
    Num Shares 54.8 Million
    EPS -2.05
    Price-to-Earnings (P/E) Ratio -0.31
    Price-to-Sales 0.00
    Price-to-Book 0.43
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.69
    Resistance 3 (R3) 0.69 0.67 0.68
    Resistance 2 (R2) 0.67 0.65 0.67 0.68
    Resistance 1 (R1) 0.65 0.65 0.66 0.65 0.67
    Pivot Point 0.63 0.63 0.63 0.63 0.63
    Support 1 (S1) 0.61 0.61 0.62 0.61 0.59
    Support 2 (S2) 0.59 0.61 0.59 0.58
    Support 3 (S3) 0.57 0.59 0.58
    Support 4 (S4) 0.57